Endocyte Inc fka ECYT

[Leirum]

ECYT has more in the Pipeline that the eyes meet.

The company is running trials for vintafolide as a treatment for lung cancer. That trial is currently in phase IIb testing, and key data results could come out at the end of 2014. RBC Capital Markets analyst Adnan Butt recently said that the lung cancer indication is the most important one because the market is bigger.

I would guess, the market will now concentrate on this outcome and the shorties certainly will not wait until the end of 2014 to get eggs all over the face if and when the Trial should Show positive results.